Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 22 | 2023 | 380 | 3.910 |
Why?
|
| Drug Eruptions | 2 | 2022 | 8 | 0.970 |
Why?
|
| Puerto Rico | 17 | 2023 | 1378 | 0.910 |
Why?
|
| Influenza, Human | 1 | 2023 | 83 | 0.840 |
Why?
|
| Hypersensitivity | 2 | 2019 | 30 | 0.780 |
Why?
|
| Angioedemas, Hereditary | 1 | 2020 | 1 | 0.750 |
Why?
|
| Otitis Externa | 1 | 2020 | 1 | 0.750 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2020 | 5 | 0.750 |
Why?
|
| Skin Tests | 1 | 2019 | 14 | 0.680 |
Why?
|
| Anesthetics | 1 | 2019 | 11 | 0.670 |
Why?
|
| Morpholines | 1 | 2019 | 69 | 0.660 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2017 | 1 | 0.620 |
Why?
|
| T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2017 | 1 | 0.620 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 10 | 0.610 |
Why?
|
| Dermatitis, Atopic | 1 | 2017 | 12 | 0.600 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 259 | 0.530 |
Why?
|
| Emergency Service, Hospital | 3 | 2023 | 208 | 0.510 |
Why?
|
| Humans | 34 | 2023 | 37093 | 0.510 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2014 | 5 | 0.500 |
Why?
|
| Anaphylaxis | 1 | 2013 | 14 | 0.470 |
Why?
|
| Mites | 1 | 2012 | 8 | 0.420 |
Why?
|
| Rhinitis | 1 | 2012 | 16 | 0.410 |
Why?
|
| Allergens | 1 | 2012 | 63 | 0.400 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2023 | 53 | 0.390 |
Why?
|
| Child | 14 | 2017 | 3131 | 0.380 |
Why?
|
| Allergy and Immunology | 1 | 2011 | 11 | 0.380 |
Why?
|
| Physician's Role | 1 | 2011 | 38 | 0.370 |
Why?
|
| Administration, Topical | 2 | 2020 | 40 | 0.360 |
Why?
|
| Adult | 16 | 2023 | 11712 | 0.340 |
Why?
|
| Immunoglobulin E | 5 | 2019 | 55 | 0.330 |
Why?
|
| Middle Aged | 9 | 2020 | 10129 | 0.330 |
Why?
|
| Mexican Americans | 7 | 2008 | 189 | 0.320 |
Why?
|
| Male | 19 | 2020 | 20025 | 0.290 |
Why?
|
| United States | 7 | 2023 | 4223 | 0.290 |
Why?
|
| Female | 18 | 2020 | 20969 | 0.280 |
Why?
|
| Bronchodilator Agents | 6 | 2007 | 25 | 0.240 |
Why?
|
| Child, Preschool | 3 | 2014 | 1418 | 0.230 |
Why?
|
| Immunization | 1 | 2023 | 92 | 0.220 |
Why?
|
| Hydroxyzine | 1 | 2022 | 2 | 0.220 |
Why?
|
| Patient Preference | 1 | 2023 | 44 | 0.220 |
Why?
|
| Adolescent | 12 | 2014 | 5363 | 0.220 |
Why?
|
| Beclomethasone | 1 | 2022 | 2 | 0.210 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2022 | 31 | 0.200 |
Why?
|
| Glucocorticoids | 1 | 2022 | 86 | 0.200 |
Why?
|
| Vaccination | 1 | 2023 | 288 | 0.200 |
Why?
|
| Retrospective Studies | 3 | 2023 | 2026 | 0.190 |
Why?
|
| Cross-Sectional Studies | 4 | 2014 | 2721 | 0.190 |
Why?
|
| Health Personnel | 1 | 2023 | 228 | 0.190 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2020 | 1 | 0.190 |
Why?
|
| Blister | 1 | 2020 | 2 | 0.190 |
Why?
|
| Patch Tests | 1 | 2020 | 5 | 0.190 |
Why?
|
| Neomycin | 1 | 2020 | 5 | 0.190 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 276 | 0.190 |
Why?
|
| Acetic Acid | 1 | 2020 | 16 | 0.190 |
Why?
|
| Recurrence | 1 | 2020 | 131 | 0.180 |
Why?
|
| Hydrocortisone | 1 | 2020 | 78 | 0.180 |
Why?
|
| Telemedicine | 1 | 2023 | 182 | 0.170 |
Why?
|
| Tobacco Use Disorder | 1 | 2003 | 237 | 0.170 |
Why?
|
| Aged | 5 | 2014 | 6741 | 0.170 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2019 | 8 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2008 | 767 | 0.170 |
Why?
|
| Placebos | 1 | 2019 | 37 | 0.170 |
Why?
|
| Double-Blind Method | 1 | 2019 | 286 | 0.160 |
Why?
|
| Young Adult | 3 | 2014 | 4268 | 0.160 |
Why?
|
| Mycobacterium avium Complex | 1 | 2017 | 2 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 19 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2020 | 179 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 189 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 217 | 0.150 |
Why?
|
| Smoking Cessation | 1 | 2003 | 517 | 0.140 |
Why?
|
| Tongue Diseases | 1 | 2016 | 1 | 0.140 |
Why?
|
| Angioedema | 1 | 2016 | 2 | 0.140 |
Why?
|
| Albuterol | 2 | 2007 | 9 | 0.140 |
Why?
|
| Pain | 1 | 2019 | 251 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 2379 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2017 | 1369 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 352 | 0.120 |
Why?
|
| Insect Bites and Stings | 1 | 2013 | 2 | 0.120 |
Why?
|
| Food Hypersensitivity | 1 | 2013 | 4 | 0.120 |
Why?
|
| Hospitals, Veterans | 1 | 2013 | 15 | 0.120 |
Why?
|
| Epinephrine | 1 | 2013 | 36 | 0.120 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 20 | 0.120 |
Why?
|
| Quality of Life | 3 | 2023 | 481 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2013 | 117 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2008 | 628 | 0.080 |
Why?
|
| Urticaria | 1 | 2008 | 5 | 0.080 |
Why?
|
| Linkage Disequilibrium | 2 | 2005 | 85 | 0.080 |
Why?
|
| Receptors, Prostaglandin | 1 | 2006 | 10 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 61 | 0.070 |
Why?
|
| Environmental Exposure | 1 | 2008 | 216 | 0.070 |
Why?
|
| Animals | 2 | 2013 | 15081 | 0.070 |
Why?
|
| Genotype | 5 | 2005 | 730 | 0.070 |
Why?
|
| Mexico | 4 | 2007 | 240 | 0.070 |
Why?
|
| Genetics, Population | 1 | 2005 | 100 | 0.060 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2005 | 48 | 0.060 |
Why?
|
| Social Class | 1 | 2006 | 247 | 0.060 |
Why?
|
| Absenteeism | 1 | 2004 | 11 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 1067 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2008 | 517 | 0.060 |
Why?
|
| Africa | 1 | 2023 | 76 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 16 | 0.060 |
Why?
|
| Morbidity | 1 | 2023 | 91 | 0.060 |
Why?
|
| Hospital Units | 1 | 2003 | 3 | 0.060 |
Why?
|
| Cetirizine | 1 | 2022 | 1 | 0.060 |
Why?
|
| Histamine H1 Antagonists | 1 | 2022 | 4 | 0.060 |
Why?
|
| Forecasting | 1 | 2003 | 128 | 0.050 |
Why?
|
| Forced Expiratory Volume | 3 | 2008 | 70 | 0.050 |
Why?
|
| Data Collection | 1 | 2003 | 194 | 0.050 |
Why?
|
| Severity of Illness Index | 4 | 2005 | 610 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2022 | 80 | 0.050 |
Why?
|
| Urban Population | 1 | 2004 | 333 | 0.050 |
Why?
|
| Poverty | 1 | 2004 | 348 | 0.050 |
Why?
|
| Parents | 1 | 2004 | 329 | 0.050 |
Why?
|
| Gene Frequency | 3 | 2005 | 195 | 0.050 |
Why?
|
| Prevalence | 1 | 2004 | 1455 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 227 | 0.040 |
Why?
|
| Phenotype | 2 | 2016 | 689 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 208 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 191 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2008 | 1130 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 164 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 661 | 0.040 |
Why?
|
| Macroglossia | 1 | 2016 | 1 | 0.040 |
Why?
|
| Pituitary Neoplasms | 1 | 2016 | 5 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 108 | 0.030 |
Why?
|
| Haplotypes | 2 | 2006 | 182 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2005 | 142 | 0.030 |
Why?
|
| Respiratory Function Tests | 2 | 2004 | 55 | 0.030 |
Why?
|
| Alleles | 2 | 2005 | 321 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 601 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2006 | 1492 | 0.020 |
Why?
|
| Spirometry | 1 | 2008 | 33 | 0.020 |
Why?
|
| San Francisco | 1 | 2007 | 32 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2007 | 39 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2006 | 7 | 0.020 |
Why?
|
| New York City | 1 | 2007 | 220 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 188 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2004 | 17 | 0.020 |
Why?
|
| Bronchial Provocation Tests | 1 | 2003 | 5 | 0.010 |
Why?
|
| ADAM Proteins | 1 | 2003 | 16 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 78 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 455 | 0.010 |
Why?
|
| Linear Models | 1 | 2003 | 275 | 0.010 |
Why?
|
| Lung | 1 | 2005 | 446 | 0.010 |
Why?
|
| Prognosis | 1 | 2003 | 739 | 0.010 |
Why?
|
| Logistic Models | 1 | 2003 | 923 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2003 | 753 | 0.010 |
Why?
|